<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583007</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-743-6001</org_study_id>
    <nct_id>NCT04583007</nct_id>
  </id_info>
  <brief_title>Expanded Access for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Participants Aged 2 to Less Than (&lt;) 12 Years</brief_title>
  <official_title>Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to &lt;12 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The primary purpose of this expanded access program is to evaluate clinical benefit, safety&#xD;
      of lanadelumab in pediatric participants in the United States (US) with acute attacks of HAE&#xD;
      who have completed the SHP643-301 (NCT04070326 [SPRING study]).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This expanded access program enables the pediatric participants with a high unmet medical&#xD;
      need to continue receiving lanadelumab during the interim period between completion of the&#xD;
      SHP643-301 (NCT04070326 [SPRING study]) and Food and Drug Administration (FDA) review and&#xD;
      potential approval in the age group (2 to &lt;12 years) has been granted and when the product is&#xD;
      commercially approved for this age group .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Hereditary Angioedema (HAE)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanadelumab</intervention_name>
    <description>Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks [q2wks] or for every 4 weeks [q4wks]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.</description>
    <other_name>TAK-743</other_name>
    <other_name>SHP643</other_name>
    <other_name>DX-2930</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric participants, 2 to &lt;12 years of age, with HAE who completed the SHP643-301&#xD;
             (SPRING) study and are deriving continued clinical benefit from lanadelumab treatment&#xD;
             will be invited to take part in this program&#xD;
&#xD;
          -  Participants have no suitable alternative treatment options and cannot enter a&#xD;
             lanadelumab clinical trial&#xD;
&#xD;
          -  Participant has a parent(s)/legal guardian who is informed of the nature of the&#xD;
             expanded access program and can provide written informed consent for the child to&#xD;
             participate (with assent from child when appropriate) prior to treatment&#xD;
&#xD;
          -  Participants does not have any of the following liver function test abnormalities :&#xD;
             alanine aminotransferase (ALT) greater than (&gt;)3x upper limit of normal (ULN), or&#xD;
             aspartate aminotransferase (AST) &gt;3x ULN, or total bilirubin &gt;2x ULN (unless the&#xD;
             bilirubin elevation is a result of Gilbert's syndrome)&#xD;
&#xD;
          -  Participant does not have any condition that in the opinion of the Investigator may&#xD;
             compromise their safety&#xD;
&#xD;
          -  Participant does not have a known hypersensitivity to lanadelumab or its components&#xD;
&#xD;
          -  Participant (greater than or equal to &gt;or=6 years) and/or caregiver is willing to&#xD;
             self-administer lanadelumab at home and has received documented training on&#xD;
             self-administration during the SHP643-301 (SPRING) Study&#xD;
&#xD;
          -  For Female participants of childbearing potential only:&#xD;
&#xD;
             i) Participant has agreed to be abstinent or agreed to comply with the applicable&#xD;
             contraceptive requirements of this protocol for the duration of the expanded access&#xD;
             program and for 70 days after completion ii) Participant is not pregnant or&#xD;
             breast-feeding&#xD;
&#xD;
        Note: Participants who does not satisfy the above criteria will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AIRE Medical of Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>310-998-0060</phone>
      <email>Karen@airedoc.com</email>
    </contact>
    <investigator>
      <last_name>Raffi Tachdjian, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>925-935-2599</phone>
      <email>awise@bayareaallergy.com</email>
    </contact>
    <investigator>
      <last_name>Joshua Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Asthma and Allergy</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>301-986-0670</phone>
      <email>iaaresearchwan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Henry Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hudson-Essex Allergy</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>973-759-5842</phone>
      <email>DScalcione@ProHEALTHcare.com</email>
    </contact>
    <investigator>
      <last_name>Mark Weinstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>212-241-0493</phone>
      <email>naushin.ali@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Paula Busse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>980-999-2054</phone>
      <phone_ext>304</phone_ext>
      <email>GGibson@crcharlotte.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Johnston, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>513-354-1750</phone>
      <email>CherylKB@bernsteincrc.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Institute of Clinical Research Asthma &amp; Allergy Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>419-843-8815</phone>
      <email>abbas.zaidi@ohmiallergy.com</email>
    </contact>
    <investigator>
      <last_name>Syed Rehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>214-365-0365</phone>
      <email>daguilar@aararesearch.com</email>
    </contact>
    <investigator>
      <last_name>William Lumry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yang Medicine</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G6C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>613 725-2102</phone>
      <phone_ext>261</phone_ext>
      <email>chernandez@yangmedicine.com</email>
    </contact>
    <investigator>
      <last_name>William Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin.</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>4930450518043</phone>
      <email>joanna.wollny@charite.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Maurer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang Goethe-Universitat.</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>496963016334</phone>
      <email>aygoeren-puersuen@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Emel Aygören-Pürsün, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hämophilie Zentrum Rhein Main GmbH</name>
      <address>
        <city>Moerfelden-Walldorf</city>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>4961059638909</phone>
      <email>zeynep.gutowski@hzrm.de</email>
    </contact>
    <investigator>
      <last_name>Inmaculada Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem.</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>3613251481</phone>
      <email>visy.beata@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Henriette Farkas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz. Paseo de la Castellana</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>34917277144</phone>
      <email>tercaballero@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Pedrosa Delgado, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

